Evidence-Based Management Of Anticoagulant Therapy
Publication Date: February 1, 2012
Recommendations
VKA—Initiation of Therapy
Initial Dose Selection—Loading Dose
For patients sufficiently healthy to be treated as outpatients, we suggest initiating VKA therapy with warfarin 10 mg daily for the fi rst 2 days followed by dosing based on INR measurements rather than starting with the estimated maintenance dose. (2, C)
307795
Initial Dose Selection and Pharmacogenetic Testing
For patients initiating VKA therapy, we recommend against the routine use of pharmacogenetic testing for guiding doses of VKA. (1, B)
307795
Initiation Overlap for Heparin and VKA
For patients with acute VTE, we suggest that VKA therapy be started on day 1 or 2 of LMWH or UFH therapy rather than waiting for several days to start. (2, C)
307795
Maintenance Treatment With VKAs
For patients taking VKA therapy with consistently stable INRs, we suggest an INR testing frequency of up to 12 weeks rather than every 4 weeks. (2, B)
307795
Management of the Single Out-of-Range INR
For patients taking VKAs with previously stable therapeutic INRs who present with a single out-of-range INR of 0.5 below or above therapeutic, we suggest continuing the current dose and testing the INR within 1 to 2 weeks. (2, C)
307795
Bridging for Low INRs
For patients with stable therapeutic INRs presenting with a single subtherapeutic INR value, we suggest against routinely administering bridging with heparin. (2, C)
307795
Vitamin K Supplementation
For patients taking VKAs, we suggest against routine use of vitamin K supplementation. (2, C)
307795
Anticoagulation Management Services for VKAs
We suggest that health-care providers who manage oral anticoagulation therapy should do so in a systematic and coordinated fashion, incorporating patient education, systematic INR testing, tracking, follow-up, and good patient communication of results and dosing decisions.
(Best Practice Statement) (, )
(Best Practice Statement) (, )
307795
Patient Self-Testing and Self-Management
For patients treated with VKAs who are motivated and can demonstrate competency in self-management strategies, including the selftesting equipment, we suggest PSM rather than usual outpatient INR monitoring. (2, B)
For all other patients, we suggest monitoring that includes the safeguards in our Best Practice Statement (above).
307795
Dosing Decision Support
For dosing decisions during maintenance VKA therapy, we suggest using validated decision support tools (paper nomograms or computerized dosing programs) rather than no decision support. (2, C)
307795
VKA Drug Interactions to Avoid
For patients taking VKAs, we suggest avoiding concomitant treatment with NSAIDs, including COX-2-selective NSAIDs, and certain antibiotics. (2, C)
307795
For patients taking VKAs, we suggest avoiding concomitant treatment with antiplatelet agents except in situations where benefi t is known or is highly likely to be greater than harm from bleeding, such as patients with mechanical valves, patients with acute coronary syndrome, or patients with recent coronary stents or bypass surgery. (2, C)
307795
VKA—Monitoring
Optimal Therapeutic INR Range
For patients treated with VKAs, we recommend a therapeutic INR range of 2.0 to 3.0 (target INR of 2.5) rather than a lower (INR <2) or higher (INR 3.0-5.0) range. (1, B)
307795
Therapeutic Range for High-Risk Groups
For patients with antiphospholipid syndrome with previous arterial or venous thromboembolism, we suggest VKA therapy titrated to a moderate-intensity INR range (INR 2.0-3.0) rather than higher intensity (INR 3.0-4.5). (2, B)
307795
VKA—Discontinuation of Therapy
For patients eligible to discontinue treatment with VKA, we suggest abrupt discontinuation rather than gradual tapering of the dose to discontinuation. (2, C)
307795
Parenteral Anticoagulants
UFH—Dose Adjustment by Weight
For patients starting IV UFH, we suggest that the initial bolus and the initial rate of the continuous infusion be weight adjusted (bolus 80 units/kg followed by 18 units/kg per h for VTE; bolus 70 units/kg followed by 15 units/kg per h for cardiac or stroke patients) or a fixed-dose (bolus 5,000 units followed by 1,000 units/h) rather than alternative regimens. (2, C)
307795
UFH—Dose Management of SC UFH
For outpatients with VTE treated with SC UFH, we suggest weight-adjusted dosing (fi rst dose 333 units/kg, then 250 units/kg) without monitoring rather than fi xed or weight-adjusted dosing with monitoring. (2, C)
307795
LMWH—Dosing
Should the Therapeutic Dose of LMWH Be Modified for Decreased Renal Function?
For patients receiving therapeutic LMWH who have severe renal insuffi ciency (calculated creatinine clearance <30 mL/min), we suggest a reduction of the dose rather than using standard doses. (2, C)
307795
Fondaparinux—Dosing
Fondaparinux Dose Management by Weight
For patients with VTE and body weight over 100 kg, we suggest that the treatment dose of fondaparinux be increased from the usual 7.5 mg to 10 mg daily subcutaneously. (2, C)
307795
Prevention and Management of Anticoagulant Complications
Vitamin K for Patients Taking VKAs With High INRs Without Bleeding
(a) For patients taking VKAs with INRs between 4.5 and 10 and with no evidence of bleeding, we suggest against the routine use of vitamin K. (2, B)
307795
(b) For patients taking VKAs with INRs >10.0 and with no evidence of bleeding, we suggest that oral vitamin K be administered. (2, C)
307795
Clinical Prediction Rules for Bleeding While Taking VKA
For patients initiating VKA therapy, we suggest against the routine use of clinical prediction rules for bleeding as the sole criterion to withhold VKA therapy. (2, C)
307795
Treatment of Anticoagulant-Related Bleeding
For patients with VKA-associated major bleeding, we suggest rapid reversal of anticoagulation with four-factor PCC rather than with plasma. (2, C)
307795
We suggest the additional use of vitamin K 5 to 10 mg administered by slow IV injection rather than reversal with coagulation factors alone. (2, C)
307795
Recommendation Grading
Disclaimer
Overview
Title
Evidence-Based Management Of Anticoagulant Therapy
Authoring Organization
American College of Chest Physicians
Publication Month/Year
February 1, 2012
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This article focuses on the common important management questions for which, at a minimum, low-quality published evidence is available to guide best practices.
Target Patient Population
Patients with conditions requiring anticoagulant therapy
Inclusion Criteria
Male, Female, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Emergency care, Hospice, Long term care, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Assessment and screening, Treatment, Management, Prevention
Diseases/Conditions (MeSH)
D054556 - Venous Thromboembolism, D020246 - Venous Thrombosis, D000925 - Anticoagulants, D056824 - Upper Extremity Deep Vein Thrombosis
Keywords
anticoagulation, Antithrombotic Agents, Venous Thromboembolism, deep vein thrombosis, deep venous thrombosis, Anticoagulation